FDA Sends Untitled Letter to Company Marketing Stem Cell Treatment for Autism
The US Food and Drug Administration (FDA) late last month sent an untitled letter, its third of the year, to California-based Chara Biologics for marketing an unapproved stem cell product as a possible treatment for autism and other conditions with few treatment options. FDA says the product appears to be a human cell, tissue, or